FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead

FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead

Source: 
CP Wire
snippet: 
The FDA extended the PDUFA goal date of Akcea's hereditary TTR amyloidosis drug inotersen to October 6, 2018.